R-GemOx

DRUG6 trials

Sponsors

The First Affiliated Hospital with Nanjing Medical University, Hutchmed, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Ruijin Hospital, Guangzhou Lupeng Pharmaceutical Company LTD.

Conditions

DLBCLDLBCL - Diffuse Large B Cell LymphomaDiffuse Large B-cell LymphomaRelapsed and Refractory DLBCLRelapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1

A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Not yet recruitingNCT07570017

Guangzhou Lupeng Pharmaceutical Company LTD.DLBCL

Start: 2026-05-30End: 2028-07-31Target: 42Updated: 2026-05-06

Phase 2

Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.

The First Affiliated Hospital with Nanjing Medical UniversityDiffuse Large B-cell Lymphoma

Start: 2012-08-31End: 2019-12-31Target: 60Updated: 2019-02-15

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Active, not recruitingNCT06601504

HutchmedRelapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: 2024-11-05End: 2026-11-12Updated: 2025-06-06

AZA Combined with R-GemOx for Elderly DLBCL Patients

Not yet recruitingNCT06778902

Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityDLBCL - Diffuse Large B Cell Lymphoma

Start: 2025-02-01End: 2028-01-01Target: 80Updated: 2025-01-16

Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Not yet recruitingNCT07122609

Ruijin HospitalRelapsed and Refractory DLBCL

Start: 2025-08-05End: 2027-08-15Target: 22Updated: 2025-08-14

Phase 3

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

RecruitingNCT07409428

HutchmedRelapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: 2026-03-20End: 2028-12-30Target: 240Updated: 2026-04-01

Related Papers

Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial.

2018-05-0847 citations

Interim Results From a Phase II Study Of Non-Anthracycline Combination Of Oxaliplatin-Gemcitabine Plus Rituximab (R-GemOx) As First-Line Treatment In Elderly Patients With Diffuse Large B-Cell Lymphoma

Blood2013-11-151 citations